Travere Therapeutics is a biopharmaceutical company whose mission is to identify, develop, and deliver life-changing therapies to people living with rare disease.
Living with rare disease requires courage, strength, resilience, community — and, sometimes, even a little bit of humor.
We are excited to have received accelerated approval for FILSPARI® (sparsentan) for adults living with IgA nephropathy, and are grateful to the patient community, clinical trial investigators, and all those who worked so hard to reach this milestone.
We are driven by science
The science we are advancing in rare kidney and metabolic disease has the potential to set new standards of care and bring hope to people with these rare disorders.